Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement

On March 21, 2017, Imprimis Pharmaceuticals, Inc. (the Company)
entered into securities purchase agreements (the Purchase
Agreement) with two accredited investors (the Investors), which
provides for the sale by the Company of 1,312,000 shares of its
common stock, par value $0.001 per share (the Shares), at a price
of $2.40 per Share for aggregate gross proceeds of $3,148,800
(the Offering). At the closing of the Offering (the Closing), the
Company will pay National Securities Corporation, in
consideration for its services as placement agent for the
Offering, a cash amount equal to 6% of the gross proceeds from
the sale of the Shares. The Closing is expected to take place on
or about March 27, 2017, subject to the satisfaction of customary
closing conditions.

The Shares are being offered and sold to the Companys Prospectus,
dated September 29, 2014, and Prospectus Supplement thereto as a
takedown from the Companys effective shelf registration statement
on Form S-3 (File No. 333-198675), declared effective by the
Securities and Exchange Commission on September 29, 2014. The
legal opinion of Golenbock Eiseman Assor Bell Peskoe LLP relating
to the Shares is filed as Exhibit 5.1 to this Current Report on
Form 8-K.

The form of Purchase Agreement has been filed with this Current
Report on Form 8-K to provide investors and security holders with
information regarding its terms. It is not intended to provide
any other factual information about the Company. The
representations, warranties and covenants contained in the
Purchase Agreement were made only for purposes of such agreement
and as of specific dates, were solely for the benefit of the
parties to such agreement, and may be subject to limitations
agreed upon by the contracting parties.

The foregoing is only a brief description of the material terms
of the Purchase Agreement, does not purport to be a complete
description of the rights and obligations of the parties
thereunder, and is qualified in its entirety by reference to the
Purchase Agreement that is filed as Exhibit 10.1 to this Current
Report on Form 8-K and incorporated by reference herein.

Item 8.01 Other Events

On March 22, 2017, the Company issued a press release announcing
the Offering. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

About Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) Recent Trading Information

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) closed its last trading session 00.00 at 2.42 with 63,226 shares trading hands.